Safety profiles of current antiangiogenic therapies for metastatic colorectal cancer

Safety profiles of current antiangiogenic therapies for metastatic colorectal cancer

Jyotsna FuloriaOchsner Medical Center, New Orleans, LA, USAAbstract: The biological agents approved for the treatment of patients with metastatic colorectal cancer &ndash; bevacizumab, a monoclonal antibody that targets vascular endothelial growth factor A, along with cetuximab and panitumum...

Full description

Bibliographic Details
Main Author:	Fuloria J
Format:	Article
Language:	English
Published:	Dove Medical Press 2012-08-01
Series:	OncoTargets and Therapy
Online Access:	http://www.dovepress.com/safety-profiles-of-current-antiangiogenic-therapies-for-metastatic-col-a10730

Similar Items

Role of antiangiogenic agents in the treatment of metastatic colorectal cancer
by: M. V. Zabelin, et al.
Published: (2018-05-01)

Antiangiogenic therapy for refractory colorectal cancer: current options and future strategies
by: Rachel Riechelmann, et al.
Published: (2017-02-01)

Treatment with Antiangiogenic Drugs in Multiple Lines in Patients with Metastatic Colorectal Cancer: Meta-Analysis of Randomized Trials
by: R.-D. Hofheinz, et al.
Published: (2016-01-01)

Enhanced efficacy of sitravatinib in metastatic models of antiangiogenic therapy resistance.
by: Melissa Dolan, et al.
Published: (2019-01-01)

Profile of trifluridine/tipiracil hydrochloride in the treatment of metastatic colorectal cancer: efficacy, safety, and place in therapy
by: Sunakawa Y, et al.
Published: (2017-09-01)

The role of semaphorin 4D as a potential biomarker for antiangiogenic therapy in colorectal cancer
by: Ding X, et al.
Published: (2016-03-01)

Antiangiogenic Steroids in Human Cancer Therapy
by: Richard J. Pietras, et al.
Published: (2005-01-01)

Antiangiogenic therapy
by: Avitabile T
Published: (2010-05-01)

Markers of Response to Antiangiogenic Therapies in Colorectal Cancer: Where are We Now and What should be Next?
by: E. Una Cidon, et al.
Published: (2016-01-01)

Markers of Response to Antiangiogenic Therapies in Colorectal Cancer: Where Are We Now and What Should Be Next?
by: E. Una Cidon, et al.
Published: (2016-04-01)

Mathematical modelling of neoadjuvant antiangiogenic therapy and prediction of post-surgical metastatic relapse in breast cancer patients
by: Nicolò, Chiara
Published: (2019)

Interaction between Immunotherapy and Antiangiogenic Therapy for Cancer
by: Koichi Furukawa, et al.
Published: (2020-08-01)

Antiangiogenic gene therapy of cancer: recent developments
by: Libutti Steven K, et al.
Published: (2004-06-01)

Modern aspects of antiangiogenic therapy in ovarian cancer
by: A. A. Rumyantsev, et al.
Published: (2018-11-01)

Efficacy and safety of bevacizumab-based combination therapy for treatment of patients with metastatic colorectal cancer
by: Xu R, et al.
Published: (2018-12-01)

Efficacy and safety profile of combining programmed cell death‐1 (PD‐1) inhibitors and antiangiogenic targeting agents as subsequent therapy for advanced or metastatic non‐small cell lung cancer (NSCLC)
by: Ziyi Xu, et al.
Published: (2021-09-01)

Current Status of Immunotherapy for Metastatic Colorectal Cancer
by: LIU Zhaohui, et al.
Published: (2020-12-01)

Antiangiogenic therapy reverses the immunosuppressive breast cancer microenvironment
by: Wuzhen Chen, et al.
Published: (2021-07-01)

Recent Advancements of Nanomedicine towards Antiangiogenic Therapy in Cancer
by: Anubhab Mukherjee, et al.
Published: (2020-01-01)

Escaping Antiangiogenic Therapy: Strategies Employed by Cancer Cells
by: Mauricio P. Pinto, et al.
Published: (2016-09-01)

Antiangiogenic Therapy for Diabetic Nephropathy
by: Katsuyuki Tanabe, et al.
Published: (2017-01-01)

Fucoidan/Tat peptide self-assembled nanoparticles as an antiangiogenic agent development in metastatic cancer
by: Lyu, Ya-Chi, et al.
Published: (2019)

Antiangiogenesis therapy in the treatment of metastatic colorectal cancer
by: Axel Grothey MD, et al.
Published: (2012-11-01)

Target Therapy in Unresectable or Metastatic Colorectal Cancer
by: Jae Hyun Kim, et al.
Published: (2016-12-01)

Bevacizumab in the therapy for refractory metastatic colorectal cancer
by: Mary F Mulcahy
Published: (2008-03-01)

Efficacy and safety of lenvatinib in combination with everolimus in metastatic renal cell carcinoma resistant to antiangiogenic targeted therapy: Russian multicenter observational study ROSLERCM
by: M. I. Volkova, et al.
Published: (2019-10-01)

Targeting Metastatic Colorectal Cancer with Immune Oncological Therapies
by: Norman J. Galbraith, et al.
Published: (2021-07-01)

Antiangiogenic treatment in hepatocellular carcinoma: the balance of efficacy and safety
by: Welker MW, et al.
Published: (2013-10-01)

The Epigenetic Profile of Tumor Endothelial Cells. Effects of Combined Therapy with Antiangiogenic and Epigenetic Drugs on Cancer Progression
by: Oskar Ciesielski, et al.
Published: (2020-04-01)

Designing of Chitosan Derivatives Nanoparticles with Antiangiogenic Effect for Cancer Therapy
by: Oana-Maria Dragostin, et al.
Published: (2020-04-01)

Circulating Carbonic Anhydrase IX and Antiangiogenic Therapy in Breast Cancer
by: Ursa Brown-Glaberman, et al.
Published: (2016-01-01)

New perspectives in glioblastoma antiangiogenic therapy
by: Alisa Madalina Popescu, et al.
Published: (2015-12-01)

Immunotherapies and Targeted Therapies in the Treatment of Metastatic Colorectal Cancer
by: Prashanth Rawla, et al.
Published: (2019-07-01)

Angiogenesis in metastatic colorectal cancer and the benefits of targeted therapy
by: Sun Weijing
Published: (2012-10-01)

Modern possibilities of targeted therapy in metastatic colorectal cancer
by: V A Gorbunova
Published: (2015-12-01)

Precision Therapy of Metastatic Colorectal Cancer with RAS Mutation
by: ZOU Jiayun, et al.
Published: (2021-08-01)

Refractory Metastatic Colorectal Cancer: Current Challenges and Future Prospects
by: Lam M, et al.
Published: (2020-07-01)

Current Therapeutic Strategies in BRAF-Mutant Metastatic Colorectal Cancer
by: Elisa Grassi, et al.
Published: (2021-06-01)

DNA methylation biomarkers predict progression-free and overall survival of metastatic renal cell cancer (mRCC) treated with antiangiogenic therapies.
by: Inga Peters, et al.
Published: (2014-01-01)

Lenvatinib in combination with everolimus in metastatic renal cell carcinoma resistant to antiangiogenic targeted therapy: an initial Russian experience
by: M. I. Volkova, et al.
Published: (2018-04-01)